

ID Week 2023

October 11-15, 2023
Boston, Massachusetts



Poster Presentation Schedule

Session: Antimicrobial Novel Agents		
Location: Hall B + C		
Date: Saturday, October 14		
Time: 12:15 PM – 1:30 PM US ET		
Merck	2153	Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β -lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021
Merck	2155	Low prevalence of OXA-48-like carbapenemases and susceptibility to imipenem/relebactam among non-Morganellaceae Enterobacterales isolates from Latin America – SMART 2018-2021
Pfizer	2149	In vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
Pfizer	2119	In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
Pfizer	2127	In vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2018-2021
Pfizer	2128	In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022
Pfizer	2151	In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections: ATLAS Global Surveillance Program, 2017-2021
Venatorx	2129	Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
Venatorx	2150	In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
Merck	2154	Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021
Merck	2152	Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales in the United States – SMART 2019-2021
Innoviva	2133	Surveillance of eravacycline against Gram-positive clinical pathogens, including resistant isolates, collected worldwide from multiple infection sites during 2021
Innoviva	2132	Surveillance of Eravacycline Against Enterobacterales and Non-Fermentor Clinical Isolates, Including Resistant Isolates, Collected Worldwide from multiple infection sites During 2021
Roche	2131	Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China